2021
Electroencephalography, Hospital Complications, and Longitudinal Outcomes After Subarachnoid Hemorrhage
Lissak IA, Locascio JJ, Zafar SF, Schleicher RL, Patel AB, Leslie-Mazwi T, Stapleton CJ, Koch MJ, Kim JA, Anderson K, Rosand J, Westover MB, Kimberly WT, Rosenthal ES. Electroencephalography, Hospital Complications, and Longitudinal Outcomes After Subarachnoid Hemorrhage. Neurocritical Care 2021, 35: 397-408. PMID: 33483913, PMCID: PMC7822587, DOI: 10.1007/s12028-020-01177-x.Peer-Reviewed Original ResearchConceptsHospital-acquired infectionsHospital complicationsEpileptiform abnormalitiesSubarachnoid hemorrhageCerebral ischemiaLongitudinal outcomesContinuous EEGNon-traumatic subarachnoid hemorrhageTime pointsNontraumatic subarachnoid hemorrhageEffects modelCumulative proportional odds modelRankin ScaleProspective studyFunctional outcomeResultsIn totalBaseline severityCEEG monitoringTherapeutic targetComplicationsSustained impairmentMRS assessmentSecondary analysisLongitudinal assessmentMixed effects models
2020
Soluble ST2 Is Associated With New Epileptiform Abnormalities Following Nontraumatic Subarachnoid Hemorrhage
Lissak IA, Zafar SF, Westover MB, Schleicher RL, Kim JA, Leslie-Mazwi T, Stapleton CJ, Patel AB, Kimberly WT, Rosenthal ES. Soluble ST2 Is Associated With New Epileptiform Abnormalities Following Nontraumatic Subarachnoid Hemorrhage. Stroke 2020, 51: 1128-1134. PMID: 32156203, PMCID: PMC7123848, DOI: 10.1161/strokeaha.119.028515.Peer-Reviewed Original ResearchConceptsPlasma sST2 levelsSoluble ST2Epileptiform abnormalitiesNontraumatic subarachnoid hemorrhageSubarachnoid hemorrhageSST2 levelsNeurophysiologic changesCerebral ischemiaIL-6Continuous electroencephalographyMeasures mixed-effects modelsInnate immune response pathwaysAdmission risk factorsPlasma soluble ST2Secondary brain injurySubgroup of patientsSubarachnoid hemorrhage patientsSerial plasma samplesAssociation of biomarkersInnate immune responseWilcoxon rank sum testImmune response pathwaysMixed-effects modelingRank sum testInflammatory biomarkers